SHR 9803
Alternative Names: SHR-9803Latest Information Update: 30 May 2025
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 15 Apr 2025 Preclinical trials in Solid tumours in China (Parenteral), prior to April 2025
- 02 Apr 2025 Jiangsu HengRui Medicine plans a phase I/II trial for Solid tumours (Late stage disease) in China (SC, Injection), in April 2025 (NCT06906731)